Oncoinvent announces publication of normal tissue dosimetry results in Journal of Nuclear Medicine

Data ReadoutpositiveRadspherin®Positive

AI Analysis

Summary

Oncoinvent announced publication of Phase 1 clinical dosimetry results for Radspherin® in ovarian and colorectal cancer in the Journal of Nuclear Medicine, demonstrating absorbed doses to normal organs well below toxicity-associated values and supporting a favorable safety profile.

Clinical Trial Data

Phase

Phase 1

Primary Endpoint

Met

Outcome Details

Phase 1 clinical dosimetry results published in Journal of Nuclear Medicine showing absorbed doses to normal organs well below toxicity threshold values

Importance:5/10

Sentiment:

0.65

clinical datapublicationsafety profiledosimetryradiopharmaceutical

Related Companies

$ONCIN.OL

Read the original article

Published by PR Newswire Pharma on August 11, 2026 5:29 AM

Read Original